Tivic Health Systems Rebrands as Valion Bio in Major Strategic Shift to Late-Stage Biopharma

Key Points for Investors

• Corporate Rebrand and Ticker Change: Tivic Health Systems, Inc. is now Valion Bio, Inc., with a new Nasdaq ticker symbol VBIO effective April 28, 2026. The CUSIP number remains the same.
• Strategic Transformation: The company has completed a fundamental shift—exiting consumer medical devices to focus exclusively on late-stage biopharmaceuticals.
• Lead Asset—Entolimod™: A first-in-class TLR5 agonist targeting Acute Radiation Syndrome (ARS) and oncology supportive care, with over \$140 million invested in development over 15 years. The asset is government-priority, with FDA Fast Track and Orphan Drug designations.
• BARDA and Strategic National Stockpile: Valion Bio is actively engaged with major U.S. government agencies (BARDA, DTRA, NIAID) for potential Strategic National Stockpile (SNS) procurement. If awarded, this could result in a non-dilutive, potentially nine-figure revenue event.
• Oncology Market Opportunity: The company is targeting clinical trials for Entolimod in chemotherapy-induced neutropenia, aiming for Phase IIb readiness in 2026. The global neutropenia treatment market is projected to reach \$30 billion by the early 2030s.
• Pipeline and IP Extension: Entolasta™, a next-generation TLR5 agonist, adds pipeline depth and intellectual property extension for both ARS and oncology indications.
• Acquisition of Velocity Bioworks—CDMO Platform: Valion Bio acquired Velocity Bioworks in December 2025 for \$16.3 million. This domestic biomanufacturing subsidiary enables internal and external revenue streams, having recently achieved a 200-fold scale-up in Entolimod production.
• Strategic Location: The company is headquartered in San Antonio, Texas, providing proximity to the DoD biodefense ecosystem and enhancing government relations.
• Leadership: Michael K. Handley, former CEO of Statera Biopharma, was appointed CEO in March 2026, consolidating scientific, commercial, and operational leadership for Entolimod.

Detailed Insights for Shareholders

Valion Bio’s rebranding marks a watershed moment for the company and its shareholders. The transition from a consumer medical device business to a focused, late-stage biopharmaceutical platform is now fully executed. The company’s identity change is not cosmetic—it reflects the culmination of a strategic overhaul designed to unlock both government and commercial value.

Entolimod™: A Government-Priority, Dual-Utility Asset

The crown jewel of Valion Bio is Entolimod™, a Toll-like receptor 5 (TLR5) agonist with a unique dual-utility profile. As a medical countermeasure for Acute Radiation Syndrome (ARS), Entolimod has received both FDA Fast Track and Orphan Drug designations. It is being developed under the FDA’s Animal Rule, a regulatory pathway that allows for approval based on animal efficacy data when human trials are not feasible or ethical—significantly reducing clinical execution risk.

The company is in active discussions with BARDA, DTRA, NIAID, and other government agencies for inclusion of Entolimod in the U.S. Strategic National Stockpile. If a procurement contract is secured, shareholders should note that this could result in a non-dilutive, potentially nine-figure revenue event—an immediate value inflection point for the stock.

Additionally, the cytoprotective mechanism of Entolimod supports a parallel development path in oncology supportive care, specifically chemotherapy-induced neutropenia. Physician-sponsored clinical trials are targeted for 2026, with Phase IIb readiness as an objective. The global market for neutropenia treatments is vast, expected to reach \$30 billion by the early 2030s. The introduction of Entolasta™, a next-generation TLR5 agonist, further extends the pipeline and intellectual property coverage.

Velocity Bioworks: A Strategic Manufacturing and Revenue Asset

Valion Bio’s wholly owned subsidiary, Velocity Bioworks, was acquired for \$16.3 million and provides controlled, domestic manufacturing for Entolimod. This capability is essential for government procurement, as U.S. agencies increasingly require secure domestic supply chains. The subsidiary recently delivered a 200-fold scale-up in Entolimod production using 50-liter fermentation, on time and on budget, meeting all purity and potency specifications.

Beyond internal programs, Velocity Bioworks operates as a contract development and manufacturing organization (CDMO) serving third-party early-stage biotech clients. At full utilization, management projects that Velocity Bioworks could become a self-sustaining, cash flow-positive operation—creating a non-dilutive, independent revenue stream for Valion Bio, reducing reliance on equity or debt financing.

Strategic Positioning and Macro Tailwinds

By locating its headquarters in San Antonio, Texas, Valion Bio positions itself at the heart of the U.S. Department of Defense biodefense ecosystem. The move is strategic, leveraging proximity to key institutions like Brooke Army Medical Center. The company’s ARS program aligns with federal priorities to rebuild national preparedness infrastructure, and allied governments are also evaluating Entolimod for their own stockpiling programs. This multi-jurisdictional opportunity could further expand revenue and de-risk the business model.

Leadership to Guide the Next Chapter

The appointment of Michael K. Handley as CEO in March 2026 is significant. Handley’s track record includes advancing Entolimod at Statera Biopharma and developing deep institutional relationships with key regulatory and government stakeholders. His leadership brings continuity and expertise critical for navigating late-stage development and commercialization.

Potential Price-Sensitive Details for Shareholders

• Government procurement contracts (SNS inclusion) for Entolimod could deliver near-term, non-dilutive revenue in the nine-figure range.
• Velocity Bioworks’ ability to generate independent CDMO revenue could reduce future dilution risk and provide steady cash flow.
• Progress in oncology clinical trials, or positive regulatory developments, would likely be significant share price catalysts.
• Execution risks remain: success depends on government procurement, regulatory approvals, and commercialization timelines. The company cautions investors about forward-looking statements and notes several risks, including regulatory hurdles, market changes, the need for additional capital, and maintaining Nasdaq listing compliance.

Conclusion

Valion Bio’s completed transformation positions the company for potentially transformative value creation. The new strategic focus, supported by a validated late-stage asset, government engagement, and a scalable manufacturing platform, creates multiple commercial and non-dilutive revenue opportunities.

Shareholders should monitor upcoming milestones: government contract announcements, oncology trial initiations, and updates on Velocity Bioworks’ CDMO business. Each could materially impact the company’s valuation.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties. Investors should review Valion Bio’s filings with the SEC, including the most recent Annual Report and risk disclosures, prior to making any investment decisions.

View Tivic Health Systems, Inc. Historical chart here